Skip to main content
EJNMMI Research
Fig. 4 | EJNMMI Research

Fig. 4

From: Enhancing the therapeutic effects of in vitro targeted radionuclide therapy of 3D multicellular tumor spheroids using the novel stapled MDM2/X-p53 antagonist PM2

Fig. 4

a UM-SCC-74B spheroid growth over time after treatment with 30 kBq and 100 kBq 177Lu-AbN44v6 as well and 100 kBq 177Lu-rituximab as well as representative images of treated spheroids. b UM-SCC-74B spheroid growth over time after treatment with 20 μM of PM2 and the combination of 20 μM PM2 with 30 kBq and 100 kBq 177Lu-AbN44v6 and 100 kBq 177Lu-rituximab as well as representative images of treated spheroids. n ≥ 4, error bars presented as 95% confidence intervals. A combination of 20 μM PM2 with 30 kBq 177Lu-AbN44v6 differed significantly from monotherapies (p < 0.001). A combination of 20 μM PM2 with 100 kBq 177Lu-AbN44v6 differed significantly from monotherapies (p < 0.0001 and p < 0.001 for PM2 and TRNT, respectively). The combination of 20 μM PM2 with 100 kBq 177Lu-rituximab did not differ from combination therapy of PM2 with 177Lu-AbN44v6 as assessed with one-way ANOVA followed by Tukey’s multiple comparisons test

Back to article page